12.84
-0.16%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jiangsu Lianhuan Pharmaceutical Co
Its shares trade on Shanghai under the ticker 600513.SS. It has been listed since 19 March 2003. In the fiscal year to 31 December 2024, it reported revenue of CN¥2.16bn and net income of CN¥84.2m. At that date it held total assets of CN¥3.02bn and shareholders' equity of CN¥1.40bn.
Jiangsu Lianhuan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and sale of chemicals and pharmaceutical products. The company is headquartered in Yangzhou, Jiangsu. The company went IPO on 2003-03-19. The firm's products are mainly applied as urinary system medicines, antihistamines and cardiovascular medicines. The firm's products include Epristeride Tablets, Ebastine Tablets, Felodipine Tablets, Felodipine Sustained Release Capsules, Simvastatin Tablets, Lumbrokinase Capsulesand and Balofloxacin Tablets. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Mar 2003
- Employees
- 1,276
- Website
- lhpharma.com ↗
Leadership
Pay as last reported
- Mr. Zhenhua QianChairman of the Board, Secretary of the Board, since 2024
- Mr. Bin TuVice Chairman of the Board, since 2024
- Mr. Hao XueChief Financial Officer
- Mr. Ben NiuGeneral Manager, Director, since 2020
- Mr. Qisong ChuDeputy General Manager
- Mr. Changkun HuDeputy General Manager
- Mr. Yi ShenDeputy General Manager
- Mr. Liangsheng ZhouChief Engineer
- Mr. Wendong LiuDirector
- Mr. Chunlai XiaDirector, since 2016
- Ms. Ying ChenIndependent Director
- Ms. Fang FangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Jiangsu Lianhuan Pharmaceutical's Epristeride Tablets target urinary system medicine segment in China.
- The company's Felodipine Sustained Release Capsules are used in cardiovascular medicine applications domestically.
- Lumbrokinase Capsules and Balofloxacin Tablets are distributed in overseas markets for global pharmaceutical demand.
Weaknesses
- Jiangsu Lianhuan Pharmaceutical's antihistamine product line lacks international market presence.
- The firm's Ebastine Tablets are limited to domestic sales within China's pharmaceutical sector.
- Simvastatin Tablets face competition from established domestic pharmaceutical brands.
Opportunities
- Expanding Epristeride Tablets into overseas markets for urinary system medicine growth.
- Increasing Felodipine Sustained Release Capsules sales in cardiovascular medicine segments globally.
- Growing demand for Lumbrokinase Capsules in international pharmaceutical markets.
Threats
- Competition from domestic pharmaceutical companies in the antihistamine segment.
- Regulatory changes affecting urinary system medicine approvals in China.
- Overseas market volatility impacting distribution of Balofloxacin Tablets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.